CA2373993A1 - Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives - Google Patents

Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives Download PDF

Info

Publication number
CA2373993A1
CA2373993A1 CA002373993A CA2373993A CA2373993A1 CA 2373993 A1 CA2373993 A1 CA 2373993A1 CA 002373993 A CA002373993 A CA 002373993A CA 2373993 A CA2373993 A CA 2373993A CA 2373993 A1 CA2373993 A1 CA 2373993A1
Authority
CA
Canada
Prior art keywords
activating agent
ligand
methods
nuclear imaging
biotin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002373993A
Other languages
English (en)
Other versions
CA2373993C (fr
Inventor
Gregory M. Lanza
Samuel A. Wickline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barnes Hospital
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1999/011491 external-priority patent/WO2000071172A1/fr
Publication of CA2373993A1 publication Critical patent/CA2373993A1/fr
Application granted granted Critical
Publication of CA2373993C publication Critical patent/CA2373993C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
CA002373993A 1999-05-25 1999-05-25 Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives Expired - Fee Related CA2373993C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/011491 WO2000071172A1 (fr) 1997-12-12 1999-05-25 Système de liaison spécifique de site, compositions d"imagerie nucléaire et méthodes y relatives

Publications (2)

Publication Number Publication Date
CA2373993A1 true CA2373993A1 (fr) 2000-11-30
CA2373993C CA2373993C (fr) 2008-11-18

Family

ID=22272830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373993A Expired - Fee Related CA2373993C (fr) 1999-05-25 1999-05-25 Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives

Country Status (3)

Country Link
JP (1) JP2003521475A (fr)
AU (1) AU771565B2 (fr)
CA (1) CA2373993C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
EP2708244A1 (fr) * 2012-09-14 2014-03-19 Stichting Katholieke Universiteit Agent de contraste et son utilisation pour l'imagerie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
EP0857071A1 (fr) * 1995-09-18 1998-08-12 Mallinckrodt Medical, Inc. Composes de biotine (radio) marques

Also Published As

Publication number Publication date
AU4097599A (en) 2000-12-12
CA2373993C (fr) 2008-11-18
AU771565B2 (en) 2004-03-25
JP2003521475A (ja) 2003-07-15

Similar Documents

Publication Publication Date Title
CA2222544A1 (fr) Systeme de liaison a des sites specifiques, procede et composition d'imagerie
Tiefenauer et al. Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging
US5792445A (en) Polymers and copolymers of acrylic acid MRI of the digestive tract of patients
WO1998016257A3 (fr) Microparticules stabilisees et leur utilisation comme agent de contraste en imagerie a ultrasons
BR9814393A (pt) Micropartìculas e uso terapêutico ou diagnóstico delas
CA2090700A1 (fr) Anticorps modifies avec temps de clairance retarde
AU611196B2 (en) Modified antibodies for enhanced clearance
WO2002087498A8 (fr) Compositions d'imagerie diagnostique, leurs methodes de synthese et utilisation
IS2059B (is) Lífefnafræðilega virkjuð skuggaefni til myndgreiningar
MY109875A (en) Novel formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight surfactants.
MX9101999A (es) Agentes complejantes e inmunoreactivos radioactivos de objetivo, utiles en composiciones y metodos de formacion de imagen terapeuticos y de diagnostico.
CA2451852A1 (fr) Microspheres de proteines polymerisees paramagnetiques et procedes de fabrication de ces dernieres
EP1808155A3 (fr) Hybrides de protéines de sérum d'anticorps
CA2200061A1 (fr) Recipient contenant une composition polyphasique et s'utilisant dans des applications diagnostiques et therapeutiques
CA2220008A1 (fr) Procede et composition de visualisation de tumeurs
WO1992019213A3 (fr) Amelioration de l'absorption, par les tissus anormaux, d'anticorps, d'agents specifiques a certaines tumeurs ou de conjugues de ces derniers pour l'imagerie a des fins de diagnostic ou la therapie
JP2004518704A5 (fr)
CA2137561A1 (fr) Photoactivation de proteines en vue de leur conjugaison
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
GB2298368B (en) Medical needle assembly for use in ultrasound imaging
CN1909931A (zh) 用于分子成像的超声造影剂
NO933421L (no) Konstrastmiddel
AU2722292A (en) Encapsulated particles useful as contrast agents in ultrasound and x-ray imaging compositions and methods
CA2373993A1 (fr) Systeme de liaison specifique de site, compositions d'imagerie nucleaire et methodes y relatives
Paganelli et al. Pretargeting of carcinomas with the avidin-biotin system

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20110525